ISU203 / ISU Abxis - LARVOL DELTA

[Newspim LaCiro] ISU Abxis “Goal for technology transfer of ‘ISU104’ and ‘ISU203’ within the year” [Google translation] (Nate) - "Isu Abxis, a biotech specializing in rare disease treatments, is aiming to transfer technology for new drug candidates within the year. This year, the strategy is to continue the surplus trend by expanding overseas markets and secure external expansion through technology transfer....The new drug candidates that Isu Abxis is currently exploring for technology transfer include an anti-cancer antibody treatment (ISU104) and an Alzheimer's treatment (ISU203)."

Licensing / partnership • Alzheimer's Disease • CNS Disorders • Oncology • Solid Tumor

Isu Abxis, first quarter operating profit of KRW 3.2 billion… 144% increase in sales [Google translation] (eDaily) - "An ISU Abxis official said, 'We expect top-line and profit growth to continue due to the expansion of overseas exports,' adding, 'At the same time, we are also pursuing overseas licensing out (LO) of anti-cancer antibody treatment ISU104 and Alzheimer’s treatment ISU203 as a key task, so this year, we will focus on research and development (R&D), he said, 'and we will also achieve results.'"

Licensing / partnership • Alzheimer's Disease • Oncology • Solid Tumor